Amend the bill in section 1 in subsection 2-A in the 3rd line (page 1, line 5 in L.D.) by inserting after the following: " pharmacist" the following: ' as authorized by a practitioner'
Amend the bill in section 4 in §13841 in subsection 2 in paragraph D in the 2nd line (page 2, line 31 in L.D.) by striking out the following: " the practitioner" and inserting the following: ' a practitioner who is treating the patient, as long as the action is reported to the practitioner in a timely manner as determined by rules adopted pursuant to section 13846'
Amend the bill in section 4 in §13842 in subsection 2 in paragraph A in the 4th line (page 3, line 4 in L.D.) by striking out the following: " or" and inserting the following: ' of'
Amend the bill in section 4 in §13842 in subsection 2 in paragraph A in the last line (page 3, line 5 in L.D.) by striking out the following: " the area" and inserting the following: ' each clinical area'
Amend the bill in section 4 in §13842 in subsection 2 in paragraph B in the 4th line (page 3, line 9 in L.D.) by striking out the following: " or" and inserting the following: ' of'
Amend the bill in section 4 in §13842 in subsection 2 in paragraph B in the 4th line (page 3, line 9 in L.D.) by striking out the following: " the area" and inserting the following: ' each clinical area'
Amend the bill in section 4 in §13842 in subsection 2 in paragraph C in the 4th line (page 3, line 14 in L.D.) by striking out the following: " or" and inserting the following: ' of'
Amend the bill in section 4 in §13842 in subsection 2 in paragraph C in the 4th line (page 3, line 14 in L.D.) by striking out the following: " the area" and inserting the following: ' each clinical area'
Amend the bill in section 4 in §13843 in subsection 1 in the 2nd line (page 3, line 20 in L.D.) by inserting after the following: " board" the following: ' and the licensing board that licenses the practitioner'
Amend the bill in section 4 in §13843 by striking out all of subsection 6 and inserting the following:
Amend the bill in section 4 by striking out all of §13846 and inserting the following:
The board and the Board of Licensure in Medicine, after consultation with the Department of Health and Human Services, shall adopt rules to implement this subchapter. The rules must include rules establishing record-keeping and documentation procedures and reporting requirements and must allow for electronic filing when possible. Rules adopted pursuant to this section are routine technical rules as defined in Title 5, chapter 375, subchapter 2-A.
Nothing in this subchapter may be construed to limit the scope of practice of a pharmacist pursuant to this chapter or to apply to collaborative practice agreements entered into between a pharmacist and a hospital solely for the treatment of inpatients at the hospital.’
Amend the bill by relettering or renumbering any nonconsecutive Part letter or section number to read consecutively.
SUMMARY
This amendment makes the following changes to the bill.
1. It amends the definition of "collaborative drug therapy management" to require authorization by a practitioner in accordance with the collaborative practice agreement.
2. It amends the scope of authority for pharmacists engaging in collaborative drug therapy management by clarifying that the agreement must be with a practitioner who is treating the patient and that all actions must be reported to the practitioner in a timely manner according to rules jointly adopted by the Maine Board of Pharmacy and the Board of Licensure in Medicine.
3. It requires a pharmacist to submit a copy of the collaborative practice agreement to the Maine Board of Pharmacy and the board that licenses the practitioner.
4. It requires that a collaborative practice agreement include a provision that states that activity in the initial 3 months of all collaborative practice agreements is limited to monitoring drug therapy. After the initial 3 months, the practitioner and pharmacist are required to meet to review the agreement and determine its scope, which may after the initial 3-month period include a pharmacist's initiating, monitoring, modifying and discontinuing a patient’s drug therapy and reporting to the practitioner in a timely manner as determined by rule.
5. It requires the Maine Board of Pharmacy and the Board of Licensure in Medicine to jointly adopt rules to implement the subchapter on collaborative drug therapy management enacted by the bill.
6. It adds an exemption to clarify that the subchapter on collaborative drug therapy management enacted by the bill does not limit the scope of practice of a pharmacist under the Maine Pharmacy Act or prohibit a pharmacist that is employed by a hospital from participating in a collaborative practice agreement with the hospital solely for treatment of inpatients.